Clinical Tumor Immunology (eBook)

Maurice J. Staquet, Joseph Wybran (Herausgeber)

eBook Download: PDF

2014 | 1. Auflage
298 Seiten
Elsevier Science (Verlag)
978-1-4831-4015-5 (ISBN)

Infos

Clinical Tumor Immunology contains the proceedings of the Symposium of Clinical Tumor Immunology held in Brussels, Belgium, on May 26-29, 1975) and organized by the European Organization for Research on Treatment of Cancer in cooperation with the Department of Immunology of the University Hospital of Brussels. The papers explore progress in the field of clinical tumor immunology and cover topics ranging from general mechanisms in tumor immunity to tumor antigens and immunotherapy. A classification of leukemias and lymphomas is also presented. Comprised of 48 chapters, this book begins with an overview of the biological activities of the circulating thymic hormone, followed by a discussion on macrophage secretions affecting the growth of other cells. The reader is then introduced to immune cellular mechanisms at the site of the tumor; the use of the leukocyte migration technique in studies of tumor-directed cellular immunity in malignant melanoma; and immunological approaches to the identification of leukemic cells. Subsequent chapters deal with preclinical approaches in tumor immunochemotherapy; mediation of immune responses to human tumor antigens with 'immune' RNA; and the role of transfer factor in human cancer. This monograph will be of interest to oncologists and immunologists.

---

Clinical Tumor Immunology contains the proceedings of the Symposium of Clinical Tumor Immunology held in Brussels, Belgium, on May 26-29, 1975) and organized by the European Organization for Research on Treatment of Cancer in cooperation with the Department of Immunology of the University Hospital of Brussels. The papers explore progress in the field of clinical tumor immunology and cover topics ranging from general mechanisms in tumor immunity to tumor antigens and immunotherapy. A classification of leukemias and lymphomas is also presented. Comprised of 48 chapters, this book begins with an overview of the biological activities of the circulating thymic hormone, followed by a discussion on macrophage secretions affecting the growth of other cells. The reader is then introduced to immune cellular mechanisms at the site of the tumor; the use of the leukocyte migration technique in studies of tumor-directed cellular immunity in malignant melanoma; and immunological approaches to the identification of leukemic cells. Subsequent chapters deal with preclinical approaches in tumor immunochemotherapy; mediation of immune responses to human tumor antigens with "e;immune"e; RNA; and the role of transfer factor in human cancer. This monograph will be of interest to oncologists and immunologists.

Inhalt

Front Cover 1
Clinical Tumor Immunology 4
Copyright Page 5
Table of Contents 6
Introduction 10
The Immunological Dream of an Oncologist 12
Eortc, 
14 
PART 1: GENERAL MECHANISMS IN TUMOR IMMUNITY 
18 
CHAPTER 1. BIOLOGICAL ACTIVITIES OF THE CIRCULATING THYMIC HORMONE 
20 
THETA CONVERSION 
21 
MITOGEN RESPONSES 21
AUTOLOGOUS ROSETTES [16,17] 22
ANTIGEN-INDUCED CAPPING 22
STEROID RECEPTORS 22
SUPPRESSOR T-CELLS 23
CONCLUSIONS 23
REFERENCES 24
CHAPTER 2. MACROPHAGE SECRETIONS AFFECTING THE GROWTH OF OTHER CELLS 
26 
ABSTRACT 26
ABBREVIATIONS 26
ACTIVE ROLE OF MACROPHAGES IN TUMOUR REJECTION 26
MACROPHAGE AS A SECRETORY CELL [11] 27
SECRETION BY MACROPHAGES OF FACTORS AFFECTING THE GROWTH OF OTHER CELLS 
27 
STUDIES ON A CYTOSTATIC FACTOR RELEASED BY CULTURED NORMAL MACROPHAGES 29
ACKNOWLEDGEMENTS 33
REFERENCES 34
CHAPTER 3. IMMUNE CELLULAR MECHANISMS AT THE SITE OF THE TUMOR 
36 
ABSTRACT 36
INTRODUCTION 36
MATERIAL AND METHODS 37
RESULTS 38
DISCUSSION 43
REFERENCES 44
PART 2: TESTS IN CANCER PATIENTS 46
CHAPTER 4. T-CELL ROSETTES IN HUMAN CANCER 
48 
ABSTRACT 48
INTRODUCTION 48
ROSETTE FORMING CELLS ARE T-CELLS 49
HUMAN CANCER 50
THE FUNCTIONAL MEANING OF ACTIVE T-ROSETTES FORMING CELL 52
CONCLUSIONS 55
ACKNOWLEDGEMENTS 55
REFERENCES 55
CHAPTER 5. CELL-MEDIATED CYTOTOXICITY IN VITRO. MECHANISMS AND RELEVANCE TO TUMOR IMMUNITY 
58 
INTRODUCTION 58
ASSAY SYSTEMS 58
NATURE OF EFFECTOR CELLS 59
SPONTANEOUS LYTIC ACTIVITY OF NORMAL PERIPHERAL BLOOD 60
RELEVANCE TO TUMOR IMMUNITY 61
REFERENCES 62
CHAPTER 6. FUNCTION AND EVALUATION OF HUMAN K-CELLS 
64 
SUMMARY 64
INTRODUCTION 64
QUANTITATION OF CYTOTOXIC CELLS 65
NATURE OF K-CELLS AND THEIR DISSOCIATION FROM OTHER LEUKOCYTES 
68 
REFERENCES 69
CHAPTER 7. LYMPHOCYTE STIMULATION TEST FOR DETECTION OF TUMOR SPECIFIC REACTIVITY IN HUMANS 
72 
METHODOLOGICAL CONSIDERATIONS 72
REPRODUCIBILITY 74
DOSE-RESPONSE RELATIONSHIPS 74
THE STRENGTH OF REACTIVITY AND THE FREQUENCY OF ATS POSITIVE HUMAN TUMORS 
76 
USE OF SOLID TUMOR EXTRACTS AS ANTIGEN 77
THE EFFECT OF AUTOLOGOUS SERUM IN THE ATS SYSTEM 78
TUMOR-BOUND IMMUNOGLOBULIN 81
GENERAL CONCLUSIONS 84
ACKNOWLEDGEMENTS 84
REFERENCES 84
CHAPTER 8. THE LEUCOCYTE MIGRATION TECHNIQUE IN STUDIES OF TUMOR-DIRECTED CELLULAR IMMUNITY IN MALIGNANT MELANOMA 
86 
INTRODUCTION 86
PATIENTS 86
METHODS 86
RESULTS 87
DISCUSSION 90
ACKNOWLEDGEMENTS 92
REFERENCES 92
CHAPTER 9. DETECTION OF CELL-MEDIATED IMMUNITY AGAINST TUMOR-ASSOCIATED ANTIGENS OF HUMAN BREAST CARCINOMA BY MIGRATION IN HIBITION AND LYMPHOCYTE-STIMULATION ASSAYS 
94 
ABSTRACT 94
INTRODUCTION 94
MATERIALS AND METHODS 95
RESULTS 97
DISCUSSION 101
REFERENCES 103
PART 3: TUMOR ANTIGENS 104
CHAPTER 10. THE USE OF CEA (CARCINOEMBRYONIC ANTIGEN) AND OTHER CARCINOFOETAL ANTIGENS IN HUMAN CANCER 
106 
ABSTRACT 106
INTRODUCTION 106
I. THE CARCINOEMBRYONIC ANTIGEN (CEA) 
107 
II. THE ALPHA-FOETO-PROTEIN (AFP) 114
III. THE ALPHA-2H-FERROGLOBULINE (a-2H-Fe) 
117 
REFERENCES 118
PART 4: HL-A IN CANCER 122
CHAPTER 11. HL-A AND CANCER 124
ABSTRACT 124
INTRODUCTION 124
HL-A AND NON-MALIGNANT DISEASES 
125 
HL-A AND CANCER 
126 
DISCUSSION 127
REFERENCES 127
PART 5: CLASSIFICATION OF LEUKEMIAS AND LYMPHOMAS 
130 
CHAPTER 12. IMMUNOLOGICAL APPROACHES TO THE IDENTIFICATION OF LEUKAEMIC CELLS 
132 
ABBREVIATIONS 132
CELL SURFACE PHENOTYPING 133
ACKNOWLEDGMENTS 138
REFERENCES 138
CHAPTER 13. LYMPHOCYTE MEMBRANE MARKERS IN B-CELL PROLIFERATIONS AND HUMAN NON-HODGKIN'S LYMPHOMAS 
140 
ABSTRACT 140
INTRODUCTION 140
METHODS AND THEIR CRITICAL EVALUATION 140
CHARACTERISTICS OF B-CELL PROLIFERATION 142
MEMBRANE MARKERS IN HUMAN NON-HODGKIN'S LYMPHOMAS 144
ACKNOWLEDGEMENTS 146
REFERENCES 146
CHAPTER 14. CLASSIFICATION OF LEUKEMIAS AND HEMATOSARCOMAS BASED ON CELL MEMBRANE MARKERS AND SCANNING ELECTRON MICROSCOPY 
148 
ABSTRACT 148
INTRODUCTION 149
METHODOLOGICAL CONSIDERATIONS 149
RESULTS 150
DISCUSSION 158
REFERENCES 159
PART 6: IMMUNOTHERAPY 162
CHAPTER 15. PRECLINICAL APPROACHES IN TUMOR IMMUNOCHEMOTHERAPY 
164 
REFERENCES 173
CHAPTER 16. LEVAMISOLE IN RESECTABLE HUMAN BRONCHOGENIC CARCINOMA 
176 
ABSTRACT 176
INTRODUCTION 176
PATIENTS 177
METHODS 
177 
RESULTS 179
COMMENTS 184
REFERENCES 185
CHAPTER 17. MEDIATION OF IMMUNE RESPONSES TO HUMAN TUMOR ANTIGENS WITH "IMMUNE" RNA 
186 
ABSTRACT 186
INTRODUCTION 186
TRANSFER OF TUMOR IMMUNITY BY XENOGENEIC I-RNA IN ANIMALS 187
MEDIATION OF IMMUNE RESPONSES TO HUMAN TUMOR ANTIGENS 188
MEDIATION OF IMMUNE RESPONSES AGAINST RODENT TUMOR CELLS, IN VITRO, BY I-RNA 188
MEDIATION OF IMMUNE CYTOLYSIS OF HUMAN TUMOR CELLS, IN VITRO, BY XENOGENEIC "IMMUNE" RNA 
188 
INITIAL CLINICAL TRIALS OF IMMUNOTHERAPY WITH "IMMUNE" RNA 
198 
REFERENCES 206
CHAPTER 18. TRANSFER FACTOR: THE CURRENT PICTURE, WITH SPECIAL REFERENCE TO HUMAN CANCER 
208 
INTRODUCTION 208
THE QUESTION OF TRANSFER FACTOR 211
TRANSFER FACTOR AND HUMAN CANCER 215
CONCLUSION 219
ACKNOWLEDGMENT 220
REFERENCES 220
CHAPTER 19. NEW FRONTIERS OF CANCER ACTIVE IMMUNOTHERAPY 
224 
1. EXPERIMENTAL STUDIES 224
2. CLINICAL STUDIES 226
3. DEVELOPMENT 234
REFERENCES 237
CHAPTER 20. THE IMMUNOTHERAPY OF ACUTE MYELOBLASTIC LEUKAEMIA 
240 
ANTI-TUMOUR IMMUNIZATION STUDIES IN ANIMALS 242
ANTI-TUMOUR IMMUNIZATION (IMMUNOTHERAPY) IN HUMAN AML 
243 
REFERENCES 248
CHAPTER 21. IMMUNOTHERAPY OF HUMAN SOLID TUMORS: PROLONGATION OF DISEASE-FREE INTERVAL AND SURVIVAL IN MALIGNANT MELANOMA, BREAST AND COLORECTAL CANCER 
250 
SUMMARY 250
INTRODUCTION 251
PATIENTS AND METHODS 252
RESULTS 254
DISCUSSION 264
REFERENCES 265
PART 7: ABSTRACTS 
268 
CHAPTER 22. ACTIVE ROSETTES IN BCG-TREATED MELANOMA PATIENTS AND UNTREATED LEUKAEMIC CHILDREN 
268 
CHAPTER 23. LONG-TERM IMMUNOLOGICAL STUDIES IN PATIENTS WITH ADVANCED COLORECTAL CANCER 268
CHAPTER 24. IMMUNOLOGICAL STUDIES DURING IMMUNOTHERAPY IN CHRONIC MYELOCYTIC LEUKEMIA 269
CHAPTER 25. PROGNOSTIC CORRELATIONS IN MALIGNANT MELANOMA 269
CHAPTER 26. FAILURE OF ALLOGENEIC LEUKEMIC CELLS TO STIMULATE IN MIXED LYMPHOCYTE CULTURE 270
CHAPTER 27. INTERACTION OF ANTIMICROCOCCUS ANTIBODIES WITH THE LYMPHOID SYSTEM 270
CHAPTER 28. CYTOTOXIC EFFECTS OF LYMPHOCYTES FROM MELANOMA PATIENTS AND HEALTHY DONORS TESTED IN PARALLEL ON MELANOMA CELLS FROM SHORT-TERM CULTURES, A CELL LINE (NKI-4) AND T24 BLADDER CARCINOMA CELLS. PRESENCE OF TAA ON NKI-4 CELLS? 271
CHAPTER 29. LYMPHOCYTE POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 271
CHAPTER 30. ACTIVE IMMUNOTHERAPY IN ACUTE MYELOID LEUKAEMIA 272
CHAPTER 31. CIRCULATING CARCINOEMBRYONIC ANTIGEN (CEA) LEVELS IN AUSTRALIAN NORMAL AND HOSPITAL POPULATIONS 273
CHAPTER 32. INCREASED EXPRESSION OF A NORMAL LYMPHOCYTE MEMBRANE ANTIGEN ON CHRONIC LYMPHATIC LEUKEMIA CELLS 273
CHAPTER 33. STUDIES ON THE BIOLOGICAL AND CHEMICAL NATURE OF A COMPONENT IN TRANSFER FACTOR WITH IMMUNOLOGICALLY NONSPECIFIC ACTIVITY 274
CHAPTER 34. CYTOTOXICITY OF HUMAN PERIPHERAL BLOOD LYMPHOCYTES FOR BLADDER CARCINOMA CELLS AND UNRELATED SHORT-TERM CULTURES 274
CHAPTER 35. SPONTANEOUS CELL-MEDIATED CYTOTOXICITY (SCMC) OF NORMAL HUMAN LYMPHOCYTES AGAINST 51Cr-LABELED HUMAN MELANOMA CELLS: A PHENOMENON MEDIATED BY LYMPHOTOXIN 275
CHAPTER 36. THE IMMUNE REACTION TO HUMAN BREAST CANCER TISSUE 275
CHAPTER 37. THE EFFECT OF RADIOTHERAPY, AND CHEMOTHERAPY AND METHANOL EXTRACTION RESIDUE OF AN ANTI-TUBERCULOSIS VACCINE ON PATIENTS WITH LUNG CANCER 276
CHAPTER 38. ADJUVANT IMMUNOTHERAPY IN CARCINOMA OF THE PROSTATE 277
CHAPTER 39. ALKYLATING DRUG-CARRIER-IMMUNOGLOBULIN CONJUGATES FOR EXPERIMENTAL AND CLINICAL ANTI-CANCER THERAPY 277
CHAPTER 40. EFFECT OF CHEMOTHERAPEUTIC DRUGS ON THE SENSITIVITY OF TUMOR CELLS TO KILLING BY ANTIBODY AND COMPLEMENT 278
CHAPTER 41. SUPPRESSION OF IN VITRO LYMPHOCYTE STIMULATION IN CANCER PATIENTS TREATED WITH RADIOTHERAPY 278
CHAPTER 42. IMMUNO- VERSUS CHEMOTHERAPY DURING COMPLETE REMISSION (CR) OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 279
CHAPTER 43. CELL-MEDIATED CYTOTOXICITY (CMC) IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA RECEIVING IMMUNOTHERAPY 279
CHAPTER 44. REMOVAL OF SUPPRESSION OF T-LYMPHOCYTES BY PROTEOLYTIC ENZYMES IN PATIENTS WITH CANCER 280
CHAPTER 45. CLINICAL USE OF SIMULTANEOUS TWO-WAVELENGTH FLUORESCENCE MICROSCOPY IN PARAPROTEINAEMIA 280
CHAPTER 46. SPECIFICITY OF AN ANTISERUM FROM A MONKEY IMMUNIZED WITH HUMAN MELANOMA CELLS 281
CHAPTER 47. ANTI-TUMOUR IMMUNOPROTECTION BY AN IMMUNOBACTERIAL-LECTIN APPROACH 281
CHAPTER 48. LYMPHOCYTE FUNCTIONS IN MYELOMA PATIENTS 282
AUTHOR INDEX 284
SUBJECT INDEX 296

Produkt-Details

• Erscheint lt. Verlag: 18.5.2014
• Sprache: englisch
• Themenwelt: Sachbuch/Ratgeber ► Gesundheit / Leben / Psychologie ► Krankheiten / Heilverfahren
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Allgemeinmedizin
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Innere Medizin
• Themenwelt: Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
• ISBN-10: 1-4831-4015-6 / 1483140156
• ISBN-13: 978-1-4831-4015-5 / 9781483140155